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Abstract
Background: To fulfil good manufacturing requirements, analytical methods for the
analysis of pharmaceuticals for human and vetinary use must be validated. The
International Conference on Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) has published guidance documents on the
requirements for such validation activities and these have been adopted by the European
Medicines Agency, The U.S. Food and Drug Administration (FDA) and other regulatory
bodies. These guidance documents do not, however, fully address all the specific tests
required for the analysis of radiopharmaceuticals. This guideline attempts to rectify this
shortcoming, by recommending approaches to validate such methods.
Results: Recommedations for the validation of analytical methods which are specific for
radiopharmaceutials are presented in this guideline, along with two practical examples.
Conclusions: In order to comply with good manufacturing practice, analytical methods
for radiopharmaceuticals for human use should be validated.
Keywords: Radiopharmaceuticals, Validation, Radioanalytical methods
Preamble
The European Association of Nuclear Medicine (EANM) is a professional non-profit
medical association that facilitates communication worldwide among individuals pur-
suing clinical and research excellence in nuclear medicine. The EANM was founded in
1985.
This guideline has been written by members of the EANM Radiopharmacy Commit-
tee and is intended to assist professionals involved in the preparation and quality con-
trol of radiopharmaceuticals to determine when and how analytical methods should be
validated.
Background
Radiopharmaceutical preparations or radiopharmaceuticals (RPs) are medicinal products
which, when ready for use, contain one or more radionuclides included for a medical pur-
pose. The radioactive compounds in RPs may contain simple salts (e.g. [131I]sodium
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iodide), metal complexes (e.g., [99mTc]technetium exametazime), small organic molecules
(e.g. [18F]fluorodeoxyglucose) or large molecules (e.g. 125I-labelled human serum albumin)
as the active pharmaceutical ingredient. The principal radioactive ingredient may be char-
acterised and quantified on the basis of the chemistry of the molecule and the physical
properties of the radionuclide. As for any other pharmaceutical, their quality needs to be
controlled before administration to patients, to ensure that their characteristics (i.e. iden-
tity, strength, and purity) are suitable for the intended purpose. However, for quality con-
trol of radiopharmaceuticals two specific aspects which differ from conventional
pharmaceuticals must be taken into account:
 The strength of a radiopharmaceutical is defined by its radioactivity content (in
MBq), or radioactivity concentration (MBq/ml), and it follows the decay law; thus,
the strength of a radiopharmaceutical decreases with time. Radionuclides used in
the field of molecular imaging and therapy may have half-lives in the range of sec-
onds to hundreds of days.
 Whilst analytical techniques used to determine the content of non-radioactive com-
ponents (e.g. precursors, cold ligands, non-radioactive impurities, residual solvents,
etc.) of radiopharmaceutical preparations are generally the same as those used for
conventional pharmaceuticals, radioactivity determination requires specific tech-
niques, which make use of dedicated instrumentation capable of specifically detect-
ing, discriminating and quantifying the radioactivity in the sample.
Before their use in routine quality control procedures, analytical methods must be
validated. Validation is intended to ensure that the methods are suitable for their
intended purpose. This involves testing a number of parameters as defined in the guid-
ance document released by the International Conference on Harmonization of Tech-
nical Requirements for Registration of Pharmaceuticals for Human Use (ICH), which
has been adopted by the European Medicines Agency (CPMP/ICH/381/95 2014) and is
thus applicable in the Member States of the European Union (EU). The requirements
for validation according to ICH can be seen in Table 1.
Discussion
The ICH guideline provides a definition for each of the mentioned validation character-
istics and methodology, with practical hints on how to investigate specificity, linearity,
etc.; thus, it represents a general and commonly accepted basis for the validation of
analytical methods. However, in the ICH guidelines it is also stated that “approaches
other than those set forth in this guideline may be applicable and acceptable. It is the
responsibility of the applicant to choose the validation procedure and protocol most suit-
able for their product”, thus recognizing that the suggested methodology may not be
fully applicable in special cases. Although they are not specifically mentioned in ICH
text, radiopharmaceuticals are certainly a special case. With the aim to provide guid-
ance on the validation of radioanalytical methods, Table 1 has been modified to address
the specific tests required for radiopharmaceuticals (Table 2). Besides the ICH guide-
lines, there are numerous other publications describing the validation of analytical
methods for conventional pharmaceuticals. Thus, this guidance document will focus
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mainly on the validation of radioanalytical methods, with conventional methods only
touched upon in special cases.
Before designing a protocol for validation of analytical methods, it is crucial to check
which quality references apply and if these need to be supplemented by further quality
requirements, as this may determine the extent of required validation. In the 38 mem-
ber states of the Council of Europe, including all members of the European Union (EU),
the European Pharmacopoeia (Ph. Eur.) is the single, official and legal point of refer-
ence for manufacturing and quality control standards for medicinal products, including
radiopharmaceuticals. The European Pharmacopoeia contains general monographs and
a very large number of individual monographs for substances for pharmaceutical use,
written by groups of experts, based upon specifications of authorised and frequently
used preparations in Ph. Eur. member states and adopted by the Ph. Eur. Commission.
The contents and indications of these monographs are mandatory in all 38 member
states. These texts apply to both industrial and academic/hospital-based manufacturers
and for “any medicinal product which is prepared in a pharmacy in accordance with
the prescriptions of a pharmacopoeia and is intended to be supplied directly to the pa-
tients served by the pharmacy in question (commonly known as the officinal formula)”.
In the General Notices of the Ph. Eur. it is stated that “The test methods given in
monographs and general chapters have been validated in accordance with accepted sci-
entific practice and current recommendations on analytical validation. Unless otherwise
stated in the monograph or general chapter, validation of the test methods by the ana-
lyst is not required”. Thus, if a Ph. Eur. monograph exists, the quality control of a (ra-
dio)pharmaceutical is described in the monograph, i.e. which controls have to be
performed, including the related method of analysis with experimental details (e.g. sta-
tionary phase, mobile phase, flow rate, wavelength in case of HPLC analysis with UV
detector, etc.) and acceptance criteria. If the monograph is followed, the analytical
methods described do not need to be validated but must be verified in each individual
Table 1 Characteristics to be validated following ICH Q2(R1)
Type of analytical procedure
Identification Testing for impurities Assay
Quantitative Limit Dissolution Measurement only
Content / potency
Characteristic
Accuracy – + – +
Precision
Repeatability – + – +
Intermediate Precision – +a – +a
Specificityb + + + +
Detection Limit – -c + –
Quantification Limit – + – –
Linearity – + – +
Range – + – +
– signifies that this characteristic is not normally evaluated
+ signifies that this characteristic is normally evaluated
ain cases where reproducibility has been tested, intermediate precision is not needed
black of specificity of one analytical procedure could be compensated by other supporting analytical procedure(s)
cmay be needed in some cases
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laboratory, to ensure that the method has been implemented properly (e.g. system suit-
ability test, detector linearity and limit of quantification). This is especially important
for radioanalytical methods, where precise radiodetection methods are not specified in
the individual monographs. It may also be relevant to verify that the chosen formula-
tion of the preparation does not interfere with the tests described in the monograph.
Currently, over 70 monographs for radiopharmaceuticals are available, which include
most of the more frequently used radiopharmaceuticals, such as technetium-99m prep-
arations (prepared from licensed kits) and fludeoxyglucose (18F) injection ([18F]FDG). If
a monograph for a radiopharmaceutical has not been published, or in case the
monograph exists but for any reasons it is preferred to use a different method, the




The radioactivity content of a radiopharmaceutical is often determined using a dose
calibrator (ionisation chamber). Other methods such as the use of well counters (scin-
tillation detectors) may also be suitable. Further guidance can be found in the European
Pharmacopoeia (Ph. Eur. 2.2.66 2016). Validation for a given radionuclide will normally
be assured by calibration and qualification of the measurement system, and method
(product) specific validation is generally not a prerequisite.
Accuracy
Accuracy is assured by calibration using sources of radionuclides traceable to national
or international standards (e.g. cæsium-137). A daily constancy check is normally per-
formed as confirmation. Recalibration should be performed as and when necessary. In-
strument manufacturers normally provide specifications for accuracy.
Precision (repeatability)
Repeatability may be easily measured by six repeated measurements using a representa-
tive amount of radioactivity. The half-life of the radionuclide used, the quantification
limit and the linear range of the radiodetector should be taken into account when de-
termining how many repetitions it is feasible to perform. Decay correction may be re-
quired for short-lived radionuclides, thus the measured radioactivity needs to be
recalculated to t0 using the decay equation:
Ao ¼ A=e−λt
where:
A0 = activity at time 0
A = activity at time t
t = time delay in minutes
λ = decay constant (ln2/t1/2)
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Specificity
Specificity must be confirmed unless tests have ruled out the presence of relevant
quantities of impurities which may interfere with the measurement. Possible attenu-
ation due to matrix effects and geometry effects should be considered.
Linearity/range
Linearity measurements are generally part of the instrument qualification and should
be performed at least yearly for the radionuclides used and over the whole measure-
ment range. The useable measurement range should be based on the manufacturer’s
recommendations and the validation data.
Radionuclide identity
Radionuclide identity is established by assessing the physical characteristics of the ra-
dionuclide’s emissions. The energy of the radiation can be determined using a gamma-
ray or beta-particle spectrometer. Additionally, radionuclide identity can be confirmed
by approximate half-life measurements using a dose calibrator or spectrometer (gamma
or beta). As can be seen in Table 2, different validation parameters are required for
each test. Gamma-ray spectrometry is of limited usefulness for identification when the
sample may include different radionuclides emitting gamma-rays of the same energy.
This is indeed the case for positron emitters, that always emit gamma photons at 511
keV (and a sum peak at 1022 keV), due to the annihilation of positrons with the sur-
rounding electrons; here, an additional decay test may allow to discriminate between
two different positron emitting radionuclides, thus contributing to the identification of
the desired radionuclide. Half-life determinations may be performed using either a
gamma-ray spectrometer or dose calibrator, although the latter is easier and quicker to
use and usually available in any nuclear medicine department. Gamma-ray spectrom-
etry is often applied to determine the presence of long-lived radionuclide contaminants
after sufficient decay of the main radionuclide.
Half-life measurement
A preliminary knowledge of the potential contaminant radionuclides’ identities is very
important, as their half-lives and amounts affect the experimental results. For instance,
a longer-lived contaminant increases the overall sample decay time, and vice versa, and
the effect is proportional to the difference between the half-lives of the desired radio-
nuclide and contaminants. In case the latter are significantly shorter lived, compared
with the intended radioisotope, it may be useful to wait before analysing the sample, to
allow for sufficient decay of the impurity. The waiting time required for this should be
defined during method validation.
Precision (repeatability) Repeatability is normally determined during instrument
qualification for a given radionuclide as described for radioactivity content.
Specificity Half-life measurement should be specific for pure radionuclides. A suitable
measurement time should be established during the validation procedure, depending
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on the half-life of the specific radionuclide. A minimum of three measurments should
be used to determine the half-life.
Linearity/range Linearity is determined within a specified range during instrument
qualification for a given radionuclide as described for radioactivity content.
Spectrometry
Accuracy As a gamma-ray spectrometry detector provides a response in terms of emis-
sion energies, it is of paramount importance that the detector itself is suitably cali-
brated for energy using traceable standards. This is performed during instrument
qualification and is not specific to any radiopharmaceutical method.
Specificity Ideally, specificity should be evaluated using a reference standard contain-
ing the intended radionuclide in combination with one or more of the expected con-
taminant radionuclides. However, this is often unpractical, due to unsuitable half-lives
of the selected radionuclides or simply because they are not easily available from com-
mercial sources. A useful alternative may be a calibrated, multi-nuclide or single-
nuclide with multigamma-ray emission source, that may provide useful peaks in the
intended working range (usually 0–2000 keV). As resolution is an indirect measure of
specificity, results are strongly affected by the detector used, high purity germanium de-
tectors having a much higher energy resolution than sodium iodide scintillation detec-
tors (< 1% vs. > 10%). This factor should be accounted for in the conclusions related to
the validation of the method. In practice, a series of measurements with the calibrated
source(s) is performed, and the resolution factor (Rs) is calculated considering the peak
energies detected using the following equation:
Rs ¼ 1:18 Erb−Erað ÞFWHMa þ FWHMb
Where:
Erb = Energy of the peak for radionuclide « b »
Era = Energy of the peak for radionuclide « a »
FWHMb = full width at half maximum peak height for radionuclide « b »
FWHMa = full width at half maximum peak height for radionuclide « a »
Acceptance criteria might be set to Rs > 1. In the case of sodium iodide detectors, Erb
and Era will be the centroid energies.
Radiochemical identity
Identification takes advantage of the physical characteristics of the radionuclide and
physicochemical characteristics of the radiopharmaceutical. As radiopharmaceuticals
are present in tracer amounts, there is a large excess of the non-radioactive substance
which is often detectable using standard physicochemical techniques such as measure-
ment of UV absorbance. Chromatographic analyses such as HPLC, TLC or GC are gen-
erally required. The chromatographic comparison of the radioactive product peak (i.e.
retention time or retardation factor) with its non-radioactive counterpart (reference
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standard) may be used as an identification test. In some cases, it may be appropriate to
use two independent chromatographic methods to verify the identity of the radiophar-
maceutical product. The ability of the method to determine the chemical identity of
the radioactively labelled substance must be demonstrated. The retention time or re-
tardation factor of the main radioactive product peak must correspond with the reten-
tion time of the non-radioactive reference standard. When using gas or liquid
chromatography, the delay time between the in-line physicochemical (e.g. UV) and
radioactivity detectors must be accounted for. Generally, retention times should correl-
ate within ±5%. The reference standard can be analysed prior to the radioactive prod-
ucts and the two retention times compared. If retention times or retardation factors
fluctuate, then the radioactive sample can be spiked with reference standard for a com-
parison in the same analysis.
Specificity
Method validation must demonstrate that the radioactive product is resolved from any
potentially interfering radioactive impurities. Baseline separation is preferable (Rs > 1.5;
when two peaks of equal size, and Gaussian-shaped; i.e. “perfect” peaks have less than
1% overlap).
Radionuclidic purity
This is often divided into two tests:
 i) A limit test to determine the presence of short-lived radionuclides
This test is aimed at detecting impurities with half-lives comparable with that of the
main radionuclide. For impurities with shorter half-lives, it is expected that their
amount becomes negligible at the time the radiopharmaceutical is used. The test is
often performed using a sodium iodide scintillation detector and additionally acts as a
radionuclide identity test, where for example the characteristic 511 and 1022 keV peaks
from positron emitters will be seen. Normally the main peak will hamper any attempts
to detect small radionuclidic impurities and tests following decay of the main radio-
nuclide are required (see below).
Accuracy
Accuracy relies on the energy calibration and is generally assured by instrument qualifi-
cation as mentioned earlier.
Specificity
It should at least be verified that any potential impurities which may be present can be
detected at the predefined limit. Measurement times and applied radioactivity should
be established during the validation.
Detection limit
For known short-lived radionuclidic impurities, the measurement system and method
should be optimised, and the detection limit should be determined. An estimation
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based on a signal to noise ratio of 3:1 as described in the European Pharmacopoeia (Ph.
Eur. 2.2.46 2016) is appropriate.
 ii) A quantitative test (after decay) to determine the presence of longer-lived radio-
nuclidic impurities.
The absence of long-lived radionuclides in radiopharmaceutical preparations must be
ensured. For example, cyclotron produced zirconium-89 may contain yttrium-88 (t½ =
106 days) and fluorine-18 may contain tritium (t½ = 12.3 years) and various long-lived
metal radionuclides leached from cyclotron target foils (e.g. manganese-52 and 54 and
cobalt-56, 57 and 58). Radionuclides often have gamma emissions which are character-
istic and unique, and by using suitable methods such as gamma-ray spectrometry,
which is capable of detecting gamma-rays and their emission energies, it is possible to
quantify any radionuclidic impurities. In the case of tritium, a beta detection system is
essential as there are no gamma-ray emissions.
Accuracy
Accuracy may be evaluated using traceable single or multinuclide calibrated sources. It
is important that the half-life of the calibration nuclide(s) is long enough to allow meas-
urement with minimum effects due to decay. After a suitable number of acquisitions,
accuracy is then determined by comparison of calculated activity of the calibration ra-
dionuclides with the activity quantified by the instrument.
The relative content of longer-lived radionuclide contaminants increases with
time. Thus, it is important to quantify contaminants whose half-life is similar or
longer compared with that of the main radionuclide. Samples should be allowed to
decay for a suitable time, and decay time should be clearly defined. For instance,
Ph. Eur. monographs for fluorine-18 labelled radiopharmaceuticals suggest retaining
the sample at least 24 h to allow fluorine-18 to decay to a level that permits detec-
tion and quantification of the impurities. Most Ph. Eur. monographs specify a
radionuclidic purity of > 99.9%. This should be demonstrated throughout the shelf-
life of the radiopharmaceutical, which can be particularly challenging for short-
lived radionuclides. For example, [18F]FDG often has a 12 h shelf-life. Thus, the
radioactivity due to fluorine-18 decays by a factor of ca. 100 during this shelf-life
and 0.1% of radionuclidic impurities must be quantifiable relative to the radioactiv-
ity of the product at the end of its shelf-life.
Precision (repeatability)
Measurement times and detector settings should be standardised to obtain a sufficient
precision. Repeatability can be validated by six consecutive measurements of the same
sample.
Intermediate precision
If considered appropriate, testing of the same sample on different days should be used
to demonstrate intermediate precision.
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Specificity
It should be verified that any potential impurities which may be present can be detected
at the predefined limit using the measurement system. Measurement times should be
established during the validation.
Detection limit
Using gamma-ray spectrometry, the limit of quantification may be suitably replaced by
MDA (minimum detectable activity) values, which are determined by qualified software
in the instrument every time a sample is measured. MDA is a parameter depending on
several factors such as geometry, activity, background activity, counting time, etc. All
these factors should be defined during validation, in order to obtain consistent results.
Linearity
Linearity will normally be demonstrated during instrument qualification.
Range
A suitable range should be defined, based on establishing measurement times, in order




Radiochemical purity (RCP) measurements establish the content of impurities labelled
with the same radionuclide used to prepare a radiopharmaceutical, but with a different
chemical form. Strictly speaking, determination of radiochemical purity is not truly
quantitative, as it is typically calculated as the ratio between the peak area of the de-
sired radiopharmaceutical and the overall area of all the detected peaks in the radio-
chromatogram (corrected for decay). The instrument used to determine radiochemical
purity with HPLC (radio-HPLC) is the radiometric detector (radiodetector), which is
normally an in-line detector connected in series with a UV or other physicochemical
detector. The radiometric detector can be a Geiger-Müller probe, a scintillation de-
tector or a PIN diode. The validation of the method relies on the fact that all the ap-
plied sample (radioactivity) is eluted from the HPLC column. This is known as
recovery and, before any other validation parameters are considered, it is necessary to
measure this.
Recovery Certain radiochemical impurities commonly found in radiopharmaceuticals
(e.g. [18F]fluoride, [68Ga]gallium ions, 99mTc-pertechnetate) may be retained in the in-
jection system, pre-column filters, tubing or the column material itself. There are sev-
eral methods suitable for estimation of these effects, which must be considered when
validating the method. For example:
 Comparison of the injected radioactivity with the eluted radioactivity – this can be
achieved by collecting the eluent in fractions and measuring them (compared with
the calculated or measured injected radioactivity).
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 Performing a second analysis in which the sample bypasses the HPLC column and
flows directly through the radiodetector (using switching valves) and comparing the
peak areas from the two radiochromatograms, after appropriate correction for
radioactive decay. This method will not account for retention of radioactivity in the
injection system or tubing.
 By performing spike recovery experiments with samples spiked with known
amounts of a radioactive impurity (e.g. [18F]fluoride). This method requires very
careful sample preparation to be certain that the “true” radiochemical purities are
accurate.
Accuracy In some circumstances, it may be appropriate to determine accuracy of a
method using non-radioactive reference materials. This relies on the availability and de-
tectability of compounds which are detected as radioactive impurities. It can, however,
be challenging to identify such impurities due to the low masses involved (may require
highly sensitive MS detectors). In this situation accuracy may be determined during the
validation of the method for the determination of the “cold” drug substance and chem-
ical impurities. However, in this case, any characteristics specific to the radiodetector
used will not be accounted for.
If the identity of radioactive impurities is known, and if they are available, then these
can be utilised to determine accuracy, by preparing samples spiked with various
amounts of impurities and comparing the expected RCP with the measured RCP. The
results can be expressed as recovery in percentage terms. An example of the import-
ance of this concept is the determination of radiochemical purity of fluorine-18 labelled
RP’s. It is well known that free [18F]fluoride adheres to some extent to many HPLC col-
umns and considerable tailing of the peak is often observed. This is dependent on the
pH of the eluent and the column material (Ory et al. 2015). Thus, in order to validate a
radiochemical purity method where [18F]fluoride is a specified impurity, a spike recov-
ery analysis may be justified. If radio-HPLC alone is relied on for a radiochemical purity
test, a radio-TLC method may also be useful to verify the accuracy of the method.
Precision (repeatability) The repeatability of RCP determination should be deter-
mined by sequential analysis of at least 6 homogeneous samples of the radiopharma-
ceutical preparation with a radioactivity concentration close to that expected for
routine analysis. However, the half-life of the radionuclide, the limit of quantification
and the linear range of the radiodetector should be taken into account when determin-
ing how many repetitions it is feasible to perform. Peak areas obtained after integration
need to be recalculated to T0 using the decay equation:
Ao ¼ A=e−λt
Where:
A0 = corrected peak area
A =measured peak area
t = time interval in minutes between the considered injection and the first one
t1/2 = half-life in minutes
λ = decay constant = ln2/t1/2
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Peak areas, normalized for decay, may then be used to calculate the radiochemical
purity and perform a statistical analysis. A specification for precision in absolute per-
centage terms should be defined for this test, e.g. RCP ± 0.5%. In cases where the radio-
pharmaceutical is of very high radiochemical purity, it may be necessary to spike
samples with a known radioactive impurity in order to determine repeatability.
Intermediate precision Since HPLC systems are generally automated, the results
should be independent of the analyst and thus omission of this test may be justified un-
less manual injections are performed. The intermediate precision may however be
assessed by having different analysts evaluate the chromatograms obtained during the
repeatability tests. Manual integration of peaks can be subjective and may therefore
affect the precision of the method.
Specificity If the radiochemical species have non-radioactive (“cold”) counterparts
available, the assessment performed during the validation of the method for the deter-
mination of the drug substance may be applicable to the method for radiochemical pur-
ity, as it may be assumed that retention times are comparable. However, any
differences in peak width between “cold” and radioactive peaks should be considered.
Where “cold” reference samples of radiochemical impurities are unavailable, retention
times and the ability of the method to clearly separate them from the desired radio-
pharmaceutical should be assessed. A second HPLC method (different column or dif-
ferent mobile phase) may be considered to confirm that there are no radioactive
impurities coeluting with the main peak. Radiopharmaceutical product samples should
be spiked with radioactive reference standards, if available, to determine the resolution
factor. Baseline resolution of all peaks is preferable (Rs > 1.5). As mentioned above, cer-
tain radioactive impurities such as [18F]fluoride may be challenging and a secondary
complementary method may be necessary.
Quantification limit Determination of the limit of quantification (LOQ) is important,
as the expected activities of the radiolabelled impurities are usually low or very low,
and experimental tests or calculations are aimed to determine the lowest activity at
which they may be reliably quantified. In practice, considering that both the desired
product and the impurities are labelled with the same radionuclide, LOQ may be ex-
perimentally determined using samples labelled with the desired radionuclide (for in-
stance, the radiopharmaceutical itself), allowing them to decay, and performing the
HPLC analysis. Whilst a determination of LOQ is achievable, this is always related to a
specific substance (peak) and will not necessarily be appropriate for a given radioactive
impurity. Thus, validation of LOQ should determine the amount of radioactivity (radio-
activity concentration and injection volume) which must be applied in order to assure
the quantification of small amounts of radioactive impurities. LOQ is determined in
terms of absolute radioactivity or radioactivity concentration. These values must be re-
lated to the determination of RCP (in percentage terms) such that its uncertainty can
be quantified. For example, it may be defined that the RCP of a radiopharmaceutical
should be quantifiable to with 0.5%. In this case, the LOQ should be sufficient such that
a 0.5% radioactive impurity can be reliably determined.
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Linearity/range For the determination of linearity, the same samples and results used
for repeatability assessment may be used (depending on the half-life). Alternatively, se-
quential dilutions may be used. The calculated amount of radioactivity is plotted
against the measured amounts and the linear fit should comply with R ≥ 0.99. As stated
earlier, the linearity of radioactivity measurement systems is an integral part of an Op-
erational Qualification (OQ) or Performance Qualification (PQ) and, if appropriate,
these results may be sufficient. The method should be linear from LOQ to the highest
expected radioactivity concentration for a sample.
For stability studies of short-lived radiopharmaceuticals, further validation may be re-
quired in order to assure accuracy of the results at the end of shelf-life.
Robustness Robustness is normally assessed during the validation of the “cold” physi-
cochemical HPLC validation (e.g. small changes in eluent composition and pH). For
evaluation of radiochromatograms, there should be strict rules regarding peak integra-
tion and setting baselines. It may be appropriate to test the robustness of this by com-
parison of the integration of chromatograms by several different analysts (see
intermediate precision).
Radio-TLC
Radio-TLC is a relatively simple technique but can be very useful if validated correctly.
As compared with radio-HPLC it has the big advantage that all applied radioactivity is
detected and there are no concerns with recovery. Consideration should however be
given to the potential for volatile radioactive species based on knowledge of the syn-
thetic pathway and degradation products. On the other hand, TLC is a less efficient
chromatographic technique and resolution of similar compounds is often non-trivial if
at all possible.
Validation of radio-TLC methods involves the same parameters as for radio-HPLC:
Accuracy If known radioactive impurities are available, then accuracy can be verified
by spiking real samples with known amounts of these impurities. Acceptance criteria
similar to those proposed for radio-HPLC may be used.
Precision (repeatability) As for radio-HPLC, repeated measurements of the same
homogeneous sample should be performed. For radio-TLC, it is recommended to per-
form a minimum of 6 measurements. Sample application and the elution of TLC sheets
can be somewhat variable and thus requirements for repeatability should reflect this.
For short-lived or unstable radiopharmaceuticals, an assessment of repeatability may
not be possible, and the qualification of the TLC scanner must be relied upon.
Intermediate precision For radio-TLC, there can be differences in sample application
and TLC plate development techniques. Therefore, measurement of a homogeneous
sample analysed by different operators is a good way to assess this.
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Specificity As with radio-HPLC, specificity is reflected by the resolution of the product
from known impurities. The specification is normally set to baseline separation, how-
ever, lower resolution may be justified in certain cases.
Quantification limit The same considerations as for radio-HPLC should be applied.
Linearity/range The same considerations as for radio-HPLC should be applied.
Robustness This is an important parameter to be considered for radio-TLC. The treat-
ment of TLC plates/sheets can strongly influence their performance. For example,
using glass fiber sheets (iTLC sheets) it is important that they are properly stored, i.e.
in a dry environment. The effects of deliberate small changes in methods should be
evaluated. These might include, but not limited to, application volume, spot drying
time, mobile phase composition, plate development time/distance etc.
Other test methods for radiopharmaceuticals
Other general analytical methods may be of concern in the characterization of radio-
pharmaceuticals. The most important of these tests are considered below.
Determination of organic solvents
Radiopharmaceuticals often contain small amounts of organic solvents as impurities.
Furthermore, ethanol is often present in radiopharmaceutical formulations as a stabil-
iser. Gas chromatography is normally applied for these analyses, and these methods
should be validated according to the general ICH guidelines. When present as an ex-
cipient, assessment of ethanol content should be considered an assay test. When
present as a residual solvent its quantification is validated as a limit test as for other or-
ganic solvent impurities (e.g. acetonitrile, acetone, DMSO etc.).
Determination of pH using a pH-meter
As the instrument and the analysis operating procedures are very simple and
straightforward, analytical method validation tests may be used also for the qualifi-
cation of the instrument itself (and vice versa). Precision and linearity may be eas-
ily determined using calibrated standard solutions, that embrace the intended pH
working range (e.g. three standard solutions of pH 4, 7 and 10). Other ICH param-
eters do not apply. Determinations of the pH of radiopharmacuticals containing
ethanol should be considered approximate. If pH strips are used, the accuracy of
these for each radiopharmaceutical product should be validated using a calibrated
pH-meter.
Colour spot tests for Kryptofix® or tetrabutylammonium ions
Kryptofix® 222 in specific radiopharmaceutical preparations may be analysed as de-
scribed in their Ph. Eur. monographs, e.g. fludeoxyglucose (18F) injection (Ph. Eur.
monograph no. 1325 2014) by means of a spot test or using other methods, such
as GC (Ferrieri et al. 1993) analysis. In the former situation, validation may not be
required, provided that Ph. Eur. methods are followed, whilst if a non-
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pharmacopoeial method is used, validation is required. For GC methods, the stand-
ard validation requirements for impurities should followed. A validated HPLC
method is described in several Ph. Eur. monographs for analysis of tetrabutylam-
monium ions. There are also colour spot test methods published for the analysis
of tetrabutylammonium ions (e.g. Kuntzsch et al. 2014), which should be validated
before use.
Revalidation
An analytical method should be re-validated in case of:
i) changes in the RP preparation process that may result in different impurities that
have not been accounted for (e.g. when a purification method is changed, or a
different precursor is used);
ii) changes in the composition of the finished product, for example higher
radioactivity or change of excipients;
iii) significant modifications in analytical procedure; for example, the replacement of
an existing HPLC column with a new one with a different stationary phase or
significant changes to the eluent.
An objective method to evaluate the validation “status” of an analytical method is
provided by system suitability tests (SST), which are usually performed prior to the ex-
perimental analyses. Should SST results suggest that the method is no longer suitable
for the intended purpose, then a verification of maintenance, calibration and qualifica-
tion status of instruments should be performed.
Practical validation examples
Below are two real examples of validation of radioanalytical methods. It should be
noted that the acceptance criteria for the various tests, which can be found in the valid-
ation results summary tables, are based on generally accepted values and are not
intended to be hard and fast recommendations. These values may vary depending on
the type of instrument and analysis.
Validation of the determination of [18F]fluoride in [18F]fluoroethyl-L-tyrosine using radio-
TLC
Aim
To demonstrate that the applied radio-TLC method is suitable for the intended pur-
pose and complies with generally acceptable analytical method validation criteria and is
thus fit for purpose.
During the course of any method validation, a certain amount of optimisation may be
necessary in order to meet acceptance criteria.
References
ICH Topic Q2 (R1) Validation of Analytical Procedures: Text and Methodology
(CPMP/ICH/381/95)
European Pharmacopoeia 9.5, fluoroethyl-L-tyrosine (18F) injection (07/2015:2466)
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European Pharmacopoeia 9.5, 2.2.46 Chromatographic separation techniques (07/
2016:20246)
Validation characteristics
For validation purposes, this analysis is considered as a test for radiochemical purity




A radio-TLC method for [18F]fluoroethyl-L-tyrosine (fluoroethyl-L-tyrosine (18F) in-
jection, [18F]FET) is described in the European Pharmacopoiea (Ph. Eur.). This
method is intended to quantify the content of the specified impurity, [18F]fluoride.
The method validated here is very similar to the Ph. Eur. method with only minor
modifications.
 TLC Plate: TLC Silica gel 60 on aluminium backing plate (Merck)
 Mobile phase: 70/30 (acetonitrile/25 mM sodium acetate buffer, pH 3.8)
 Application: 2 μl (10 mm from bottom of plate)
 Development: 80 mm from bottom of plate
 Drying: 1 min air drying at RT
 Detection: ScanRam TLC scanner with Laura 4TM software (Lablogic) with a plastic
scintillation detector, scan speed 0.2 mm/second, scan distance 100 mm.
 Retardation factors (RF): [18F]fluoride = 0; [18F]fluoroethyl-L-tyrosine = 0.7–0.8.
Raw data is automatically corrected for radioactive decay during the course of the
TLC scan. Peaks are integrated and peak areas are derived using the software. An ex-
ample of a chromatogram where a sample of [18F]FET has been spiked with 5%
[18F]fluoride is shown below. As can be seen, the baseline is not completely flat. This is
due to some slight streaking of the sample on the TLC plate and also some slight spill-
over of radioactivity. It is therefore important to define the integration procedures for
both peaks (i.e. peak start and end distance).











(+) - not always possible
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Accuracy
Three samples of [18F]fluoroethyl-L-tyrosine were spiked with known amounts of
[18F]fluoride and the exact [18F]fluoride content was calculated. Standard radio-
TLC analysis was performed on each sample. Each sample was analysed twice and
the measured [18F]fluoride content was averaged. The results and the expected
(calculated or true) values were used to determine percentage recovery according
to the equation:









1 1.10 1.00 1.05 1.00 105.0
2 2.97 3.14 3.06 2.92 104.6
3 4.90 5.10 5.00 4.72 105.9
Careful preparation of samples is essential in order to ensure their accuracy.
Adequate volumes of each component should be used to ensure accurate
pipetting.
Precision (repeatability)
A sample of [18F]FET spiked with [18F]fluoride (ca. 5%) was applied to six TLC plates
which were developed and scanned. Standard deviation and variation coefficient (CV%)
of the radiochemical purity were calculated.
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Repeatability











The same sample of [18F]FET spiked with [18F]fluoride (ca. 5%) as used for the
repeatability test was analysed by 2 different operators (samples applied, developed,
scanned and evaluated) and the results compared.
Intermediate Precision








For [18F]fluoroethyl-L-tyrosine, there are no known radioactive impurities
besides [18F]fluoride, which may be present due to either inefficient
purification or radiolysis of the product. Specificity is represented by the
resolution of these 2 components and is calculated using the equation below
(Ph. Eur. 2.2.46):
Rs ¼ 1:18α RF2−RF1ð Þ
Wh1 þWh2
wh1, wh2 = peak widths at half-height;
α = migration distance of the solvent front.
Results from the repeatability measurement were used to calculate the resolution
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Specificity
Resolution of [18F]fluoride and [18F]FET Rs = 5.7
Limit of quantification
The quantification limit (LOQ) was measured by dilution of a sample and
measurement until a signal to noise ratio (S/N) of ca. 10:1 was received. LOQ was
determined for the specified impurity, [18F]fluoride only.
Limit of Quantification
LOQ 24 kBq/ml (S/N = 16: 1)
Linearity
Five samples of [18F]fluoride were prepared by dilution to yield a suitable range of
radioactivity concentrations. Samples were applied to TLC plates and these were
scanned without development. All results were decay corrected to the start of the first
measurement and a linear regression was applied to the results.
Linearity
Sample Radioactivity concentration (MBq/ml) Peak area (decay-corrected) Correlation coefficient (R)






The applicable radioactivity range for the samples to be analysed was calculated
based on the product specifications. [18F]FET is produced in radioactivities up to
25 GBq in 23 ml. This equates to a radioactivity concentration of 1086 MBq/ml.
The upper range of the linearity test was 1232 MBq/ml. The lower range limit
can be derived from the LOQ based on a minimum detectable [18F]fluoride
content of 0.5%. In order to meet this requirement, the applied radioactivity
concentration should be 200 times higher than the LOQ, i.e. 24 × 200 = 4.8 MBq/
ml. This equates to 110 MBq in 23 ml, which is below the minimum radioactivity
specified for the product of 400 MBq. Thus, the validated analysis range is 4.8 -
1232 MBq/ml, which complies with the radioactivity specification for the
product.
Summary of results
Summary of the validation results can be seen below.
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Validation result summary
Test Parameter Acceptance Criteria Result








RSD ≤5% RSD = 1.96%
Intermediate
Precision
RSD ≤5% (3 analysts) RSD = 2.90%





S/N ratio≥ 10 24 kBq/ml
Linearity 12–1232 kBq/ml (5 concentrations
in triplicate)
R > 0.99 R = 0.995
Range Reported value 4.8–1232 MBq/ml
Conclusions
The validation results have demonstrated that the method is acceptable with
respect to the various test parameters and thus fit for purpose. It should be noted
that the validated radioactivity concentration range should be taken into account
when performing stability studies. For the [18F]FET product used in this validation
example, a shelf life of 8 h is specified. Based on the analysis range derived from
the validation, a minimum concentration of 4.8 MBq/ml should be available at the
end of the shelf life. This equates to a concentration of 100MBq/ml at the end of
synthesis. Thus, for stability studies a minimum batch of 2.3 GBq in 23 ml should
be available.
Validation of a method for the determination of the radionuclidic purity after decay of
[18F]fluorodeoxythymidine using gamma-ray spectrometry
Aim
To verify that the method used for determination of the radionuclidic purity after a
minimum of 24 h decay of [18F]fluorodeoxythymidine ([18F]FLT) complies with the
generally accepted validation criteria and is thus fit for purpose. A Ph. Eur. monograph
exists for this product (Alovudine (18F) injection), where it is stated that the total
radioactivity due to radionuclidic impurities, measured after a decay period of at least
24 h, should be not more that 0.1%.
References
– ICH Topic Q2 (R1) Validation of Analytical Procedures: Text and Methodology
(CPMP/ICH/381/95)
– European Pharmacopoeia 9.5, alovudine (18F) injection (01/2014:2460)
– European Pharmacopoeia 9.5, 2.2.66 Detection and measurement of
radioactivity
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Validation characteristics
The characteristics to be considered during the validation of radionuclidic purity “after
decay” are depicted in the following table:











(+) - not always possible
Methods and results
Description of the analytical method
[18F]FLT (alovudine (18F) injection) is a radiopharmaceutical preparation labelled with
the radionuclide F-18 (t1/2 = 109.77min), obtained by the irradiation with 18MeV pro-
tons of an enriched 18O-water target (O-18 > 95%) via the nuclear reaction 18O(p,n)18F.
The radiopharmaceutical preparation may potentially contain contaminant radionu-
clides, formed by nuclear reactions between the incident proton beam and other iso-
topes contained in the target solution, as well as in the target holder material and
window foil materials.
Radionuclidic purity, which is the ratio between activity of the desired
radionuclide F-18, and total amount of radioactivity, may be determined using
gamma-ray spectrometry, which is capable of identifying radionuclides
exploiting their emitted energies, and whose response intensity (peak) is pro-
portional to the amount of detected activity. Specification limits for radionu-
clidic purity of this preparation are defined in the European Pharmacopoeia
monograph.
Measurement system
NaI Ortec, mod. Digibase 905–4, 3″ × 3″ crystal
Sample volume: 1 ml
Measurement time: 48 h after EOS
Measurement duration: 67 min
Calibration/validation sources (standards): multinuclide source with
Eppendorf vial geometry, volume of 1.0 ml, containing the following
radionuclides: Am-241, Cd-109, Co-57, Ce-139, Hg-203, Sn-113, Sr-85, Cs-137,
Y-88 and Co-60.
The samples to be analysed were placed close to the detector surface. As the
detector response is sensitive to various factors, such as geometry of the sample,
volume, distance of the sample from the detector surface, etc., it is of paramount
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importance that all measurements are performed keeping all these parameters
constant.
Potential impurities
The only potential radionuclidic impurity arising from the target materials itself
(18O-water) is nitrogen-13. Due to its very short half-life, this will have fully
decayed before the start of measurement. The target holder material is niobium,
which is quite inert both from chemical and “nuclear” point of views, as there are
no nuclear reactions with niobium capable of producing significant amounts of ra-
dionuclides at the applied proton energy. Thus, the major source of potential con-
taminants are the havar foils (target holder windows). Havar is an alloy made of
seven different metals, and the most significant potential impurities are listed in
the following table.
Product T1/2 Nuclear reaction Threshold (MeV)
Co-55 17.5 h 58Ni(p,α)55Co 1.36
Co-56 77 d 56Fe(p,n)56Co 5.44
Co-57 272 d 57Fe(p,n)57Co 1.65
60Ni(p,a)57Co 0.27
58Ni(p, 2p)57Co 8.31
Co-58 71 d 58Fe(p,n)58Co 3.14
Ni-57 35.6 h 58Ni(p,pn)57Ni 12.43
Cr-51 27.7 d 52Cr(p,pn)51Cr 12.27
Mn-52 5.6 d 52Cr(p,n)52Mn 5.60
Tc-95 20 h 95Mo(p,n)95Tc 2.50
Tc-96 4.3 d 96Mo(p,n)96Tc 3.30
Re-181 19.9 h 182W(p, 2n)181Re 10.65
Mo-93 m 6.85 h 93Nb(p,n)93mMo 3.60
The accuracy is the ratio between the experimental values and reference (or true)
values. Thus, in case of gamma-ray spectrometry accuracy evaluation is intertwined
with the calibration status of the detector in terms of efficiency. A couple of reference
radionuclide sealed sources, of suitable energies and activities, have here been used to
check the detector response.
For the evaluation of precision and intermediate precision, both [18F]FLT and
reference sources may be used, through repeated acquisitions. When [18F]FLT is used,
fast decrease of the activity with time should be accounted for by applying the decay
equation.
Measurement of specificity would ideally require reference samples of the major
expected contaminants, so as to discriminate between the various possible peaks.
However, they are not all available in practice, and a multinuclide source covering a
broad energy range has been used.
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Quantification limit is the lowest activity that may be reliably quantified. To correctly
evaluate this characteristic, reference standards of impurities should be available with
appropriate radioactivity concentrations, but this is often not practical, and this
parameter is thus verified using the major expected radionuclide as the reference.
Accuracy
Accuracy was evaluated by 6 measurements of a reference source containing Co-60
(T1/2 = 5.27 y), with an expected activity, based on reference activity stated on the label,






– Exp value is the activity experimentally determined by the gamma-ray spectrometer
– Calculated source value is the activity of the source stated on the label, corrected
for decay if necessary
Accuracy
Expected activity: 2545.8 Bq








Precision was evaluated by measurement of repeatability using three different [18F]FLT
samples which were each measured six times. Low activity samples were used, to
match the activity range of potential impurities.
Repeatability
Test no. 1 Starting [18F]FLT activity at T0: 370 Bq
Measurement no. Measured activity (Bq) Decay corrected activity (Bq)
1 (T0) 370 370
2 (T1) 362 372
3 (T2) 353 371
4 (T3) 341 368
5 (T4) 328 363
6 (T5) 326 370
Average 369.4 Standard deviation 3.2
CV% 0.86%
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Repeatability
Test no. 2 Starting [18F]FLT activity (at T0): 1320 Bq
Measurement no. Measured activity (Bq) Decay corrected activity
1 (T0) 1320 1320
2 (T1) 1279 1311
3 (T2) 1240 1305
4 (T3) 1225 1322
5 (T4) 1131 1307
6 (T5) 1158 1314
Average 1313 Standard deviation 6.8
CV% 0.52%
Repeatability
Test no. 3 Starting [18F]FLT activity at T0: 3021 Bq
Measurement no. Measured activity (Bq) Decay corrected activity (Bq)
1 (T0) 3021 3021
2 (T1) 2933 3008
3 (T2) 2853 3001
4 (T3) 2793 3013
5 (T4) 2710 2998
6 (T5) 2659 3017
Average 3010 Standard deviation 9.1
CV% 0.30%
Intermediate precision
Intermediate precision was assessed using a Co-60 calibrated source, by repeating the
tests on three different days. The data obtained were evaluated with analysis of variance
(Anova test). Intermediate precision is acceptable when the experimental value, F-calc is
less than F-critical for the relevant number of degrees of freedom, at a confidence level
of 0.05.
Intermediate Precision
Measurement no. Radioactivity (Bq)
Day 1 Day 2 Day 3
1 895.0 858.0 870.0
2 867.0 868.0 858.0
3 867.0 879.0 868.0
4 868.0 866.0 869.0
5 871.0 880.0 879.0
6 875.0 865.0 857.0
Average 873.83 869.33 866.83
Variance 116.9667 73.4667 67.7667
Standard deviation 10.81511 8.57127 8.23205
CV% 1.24% 0.99% 0.95%
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Variance analysis
Type of variation Degrees of freedom (DF) Average squares (AS) Fcalc
Interaction between days (n-1) ASB ASB/ASErr
Experimental error n (r-1) ASErr
Total nr-1
Results: The experimental value, Fcalc. was 0.877, while Fcritical was 3.68.
Specificity
Specificity was evaluated using a calibrated, multi-nuclide reference source, which con-
tains radionuclides whose gamma emissions cover a broad range of the energy
spectrum, and whose difference in energies may resemble those of the expected con-
taminants previously listed in Table 1. Indeed, major gamma emission energies of the
potential contaminant radionuclides are sufficiently separated from each other, and
from the main 511 keV emission due to annihilation, such that they can be efficiently
detected and quantitated using a NaI detector, whose resolution is typically in the order
of 50 keV.
Peak resolutions were determined for “pairs” of gamma emissions (that is
those which are closest in energy) using the equation described in the main
guidance:
Specificity
Composition of the multi-nuclide source (in order of increasing energy emissions):
Am-241, Cd-109, Co-57, Ce-139, Hg-203, Sn-113, Sr-85, Cs-137, Y-88, Co-60
Radionuclide Energy (keV) Resolution (Rs)
1 Am-241 59.5 Am-241/Cd-109: 1.82
2 Cd-109 88 Cd-109/Co-57: 1.92
3 Co-57 122 Sn-113/Co-57: 8.64
4 Sn-113 392 Cs-137/Sn-113: 4.47
5 Cs-137 662 Y-88(I)/Cs-137: 2.91
6 Y-88 (peak I) 898 Co-60(I)/Y-88(I): 2.94
7 Co-60 (peak I) 1173 Co-60(I)/Co-60(II): 1.44
8 Co-60 (peak II) 1837 Co-60(I)/Y-88(II): 3.62
Linearity
As F-18 activity decreases rapidly with time, instead of preparing dilutions with
different radioactivity concentrations, measurements of the same starting solu-
tion were performed, and peak areas corrected for decay. The radioactivity of
the starting solution was quantified using a calibrated activimeter (dose
calibrator).
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Linearity
Starting activity of [18F]FLT: 16488 Bq














The quantification limit was estimated using two reference sources of Co-58
(t1/2 = 70.86 d) and Co-57 (t1/2 = 271.74 d), respectively. Six measurements were per-
formed with each of the two calibrated sources.
Intermediate Presicion








Standard deviation 2.54 7.20
CV% 7.2 3.9
Based on these results, the limit of quantification is estimated to be 185 Bq. This will
easily allow for detection of any significant radionuclidic impurities to ensure the product
meets the specification for radionuclidic purity at the end of its shelf life (99.9%).
Range
The applicable measurement range was defined based on the assessment of linearity
and limit of quantification. The upper activity limit is determined by the intrinsic
characteristics of detector response, which is known to be linear provided that
deadtime does not exceed 5%. This experimentally corresponds to a value of ca. 16
kBq. The lower limit is set at 185 Bq based on the estimated limit of quantification.
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Summary of results
A summary of the validation results can be seen below.
Validation result summary
Test Parameter Acceptance Criteria Result







Repeatability 6 repetitions using [18F]FLT, 3
different activities




Intermediate Precision Fcalc. < Fcritical Fcalc. = 0.877 Fcritical = 3.68









Limit of Quantification Reported value 185 Bq
Linearity 12 samples of F-18 R > 0.99 R = 0.999
Range Reported value 185 Bq - 16 kBq
Conclusions
The validation results have demonstrated that the method is acceptable with respect to
the various test parameters and thus fit for purpose. The method is sensitive and accurate
enough to enable determination of the radionuclidic purity of [18F]fluorodeoxythymidine
with respect to long-lived radionuclides, in order to comply with the specifications for this
preparation in the European Pharmacopoeia.
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Glossary
Accuracy
The accuracy of an analytical procedure expresses the closeness of agreement between the value which is accepted either
as a conventional true value or an accepted reference value and the value found. This is sometimes termed trueness.
Analytical procedure
The analytical procedure refers to the way of performing the analysis. It should describe in detail the steps
necessary to perform each analytical test. This may include but is not limited to: the sample, the reference
standard and the preparation of reagents, use of the apparatus, generation of the calibration curve, use of the
formulae for the calculation, etc.
Detection limit
The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be
detected but not necessarily quantified as an exact value. This is normally expressed as limit of detection (LOD).
Linearity
The linearity of an analytical procedure is its ability (within a given range) to obtain test results which are directly
proportional to the concentration (amount) of analyte in the sample.
Precision
The precision of an analytical procedure expresses the closeness of agreement (degree of scatter) between a
series of measurements obtained from multiple sampling of the same homogeneous sample under the
prescribed conditions. Precision may be considered at 3 levels: repeatability, intermediate precision and
reproducibility. The precision of analytical procedure is usually expressed as the variance, standard deviation or
coefficient of variation of a series of measurements.
Repeatability
The repeatability of an individual analytical procedure expresses the precision under the same operating
conditions over a short time interval. Repeatability is also termed intra-assay precision.
Intermediate precision
The intermediate precision of an individual analytical procedure expresses within laboratory variations: different
days, different analysts, different equipment, etc.
Reproducibility
The reproducibility of an individual analytical procedure expresses the precision between laboratories
(collaborative studies, usually applied to standardisation of methodology).
Quantification limit
The quantification limit of an individual analytical procedure is the lowest amount of analyte in a sample which
can be quantitatively determined with suitable precision and accuracy. The quantification limit is a parameter of
quantitative assays for low levels of substances in sample matrices and is used particularly for the determination
of impurities and/or degradation products. This is normally expressed as limit of quantification (LOQ).
Radioactivity (assay, content or potency)
(Assay, content or potency): Quantitative determination of radionuclide decay over time. For non-spectrometric methods
of measurement of radioactivity like using ionization chambers, solid-state detectors (scintillation or semiconductors) and
liquid scintillation, the detectors are in general unable to fully discriminate all radiations coming from different radionu-
clides. Thus, the reliability of these radioactivity measurements methods requires the assurance of the absence of interfer-
ing radionuclides (radionuclidic purity) or their relative contribution to the measurement results.
Radiochemical purity
The radiochemical purity of a radiopharmaceutical preparation represents that fraction of the radionuclide present
in its stated chemical form.
Radionuclidic purity
The radionuclidic purity of a radiopharmaceutical preparation represents the proportion of the total radioactivity
that is present as the required radionuclide.
Range
The range of an analytical procedure is the interval between the upper and lower concentration (amounts) of
analyte in the sample (including these concentrations) for which it has been demonstrated that the analytical
procedure has a suitable level of precision, accuracy and linearity.
Recovery
This term denotes the obtained result from an analytical procedure with respect to the true value of the sample
under analysis and is often given as a percentage.
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Robustness
The robustness of an analytical procedure is a measure of its capacity to remain unaffected by small but
deliberate variations in method parameters and provides an indication of its reliability during normal usage.
Specificity
Specificity is the ability to assess unequivocally the analyte in the presence of components which may be
expected to be present. Typically, these might include impurities, degradation products, matrixes, etc. Lack of
specificity of an individual analytical procedure may be compensated by other supporting analytical procedure(s).
This definition has the following implications:
• Identification: to ensure the identity of an analyte.
• Purity tests: to ensure that all the analytical procedures performed allow an accurate statement of the content of
impurities of an analyte, i.e. related substances test, heavy metals, residual solvents content, etc.
• Assay (content or potency): to provide an exact result which allows an accurate statement on the content or
potency of the analyte in a sample.
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